The Claim
In the FOURIER trial, achieving very low LDL cholesterol levels (median 30 mg/dL) through PCSK9 inhibition with evolocumab was not associated with an increased risk of serious adverse events, including neurocognitive disorders, diabetes, cataracts, or hemorrhagic stroke, during treatment periods up to 3 years.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking a cholesterol drug called evolocumab to get really low LDL levels doesn’t seem to cause serious side effects like memory problems, diabetes, cataracts, or brain bleeds over 3 years, according to a major study.
See the scientific wording
Achieving very low LDL cholesterol levels (e.g., median 30 mg/dL with evolocumab in the FOURIER trial) through PCSK9 inhibition is not associated with increased risk of serious adverse events, including neurocognitive disorders, diabetes, cataracts, or hemorrhagic stroke, during treatment periods up to 3 years.
What the research says
1 studyStudy: PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
The study looked at people taking a drug called evolocumab that lowers bad cholesterol very deeply, and found no extra health risks over a few years, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.